Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug
"The [sales] growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before," Lars Fruergaard Jørgensen, president and CEO, said in a statement. "The performance in the first six months has enabled us to raise the outlook for the full year."
For 2023, the company now anticipates sales growth of 27%-33% and operating profit growth of 31%-37%, at constant exchange rates.showed that Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo, sending shares higher.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Read more »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Read more »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Read more »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Read more »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Read more »